| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 58 | 2017 | 555 | 8.330 |
Why?
|
| Methamphetamine | 21 | 2016 | 132 | 5.960 |
Why?
|
| Extinction, Psychological | 50 | 2016 | 240 | 5.730 |
Why?
|
| Cocaine-Related Disorders | 34 | 2017 | 504 | 5.650 |
Why?
|
| Self Administration | 77 | 2017 | 419 | 5.270 |
Why?
|
| Behavior, Addictive | 31 | 2021 | 317 | 5.220 |
Why?
|
| Cues | 39 | 2017 | 654 | 4.550 |
Why?
|
| Conditioning, Operant | 34 | 2015 | 241 | 4.450 |
Why?
|
| Rats | 127 | 2016 | 5300 | 3.840 |
Why?
|
| Drug-Seeking Behavior | 18 | 2017 | 213 | 3.770 |
Why?
|
| Rats, Sprague-Dawley | 89 | 2017 | 2083 | 3.490 |
Why?
|
| Amygdala | 17 | 2010 | 159 | 3.370 |
Why?
|
| Dopamine Uptake Inhibitors | 20 | 2017 | 152 | 3.340 |
Why?
|
| Haloperidol | 28 | 2002 | 95 | 2.650 |
Why?
|
| Corpus Striatum | 21 | 2012 | 279 | 2.620 |
Why?
|
| Dopamine | 24 | 2013 | 474 | 2.530 |
Why?
|
| Central Nervous System Stimulants | 10 | 2016 | 221 | 2.400 |
Why?
|
| Substance Withdrawal Syndrome | 16 | 2012 | 435 | 2.360 |
Why?
|
| Amphetamine-Related Disorders | 10 | 2016 | 92 | 2.340 |
Why?
|
| Animals | 141 | 2017 | 20881 | 2.270 |
Why?
|
| Antipsychotic Agents | 20 | 2009 | 247 | 2.120 |
Why?
|
| Behavior, Animal | 26 | 2014 | 470 | 2.090 |
Why?
|
| Prefrontal Cortex | 16 | 2021 | 640 | 1.840 |
Why?
|
| Stress, Psychological | 9 | 2013 | 824 | 1.770 |
Why?
|
| Caudate Nucleus | 13 | 2012 | 56 | 1.710 |
Why?
|
| Putamen | 13 | 2011 | 35 | 1.620 |
Why?
|
| Yohimbine | 7 | 2012 | 41 | 1.620 |
Why?
|
| Rats, Long-Evans | 19 | 2016 | 203 | 1.560 |
Why?
|
| Recurrence | 28 | 2021 | 948 | 1.450 |
Why?
|
| Motor Activity | 25 | 2015 | 621 | 1.380 |
Why?
|
| Male | 92 | 2017 | 37321 | 1.350 |
Why?
|
| Reward | 7 | 2016 | 201 | 1.350 |
Why?
|
| Motivation | 10 | 2016 | 561 | 1.290 |
Why?
|
| Nucleus Accumbens | 16 | 2016 | 417 | 1.250 |
Why?
|
| Conditioning, Classical | 7 | 2010 | 57 | 1.220 |
Why?
|
| Dose-Response Relationship, Drug | 29 | 2016 | 1745 | 1.210 |
Why?
|
| Memory Disorders | 5 | 2016 | 111 | 1.200 |
Why?
|
| Glutamic Acid | 9 | 2013 | 332 | 1.180 |
Why?
|
| Benzhydryl Compounds | 3 | 2013 | 62 | 1.160 |
Why?
|
| Substance-Related Disorders | 8 | 2021 | 1242 | 1.140 |
Why?
|
| Anxiety | 6 | 2013 | 422 | 1.090 |
Why?
|
| Sex Characteristics | 7 | 2015 | 295 | 1.050 |
Why?
|
| Appetitive Behavior | 5 | 2015 | 18 | 1.040 |
Why?
|
| Disease Models, Animal | 21 | 2017 | 2550 | 1.020 |
Why?
|
| Oxytocin | 6 | 2017 | 124 | 1.010 |
Why?
|
| Hippocampus | 6 | 2013 | 471 | 0.990 |
Why?
|
| Association Learning | 6 | 2010 | 36 | 0.990 |
Why?
|
| Estrous Cycle | 4 | 2013 | 23 | 0.970 |
Why?
|
| gamma-Aminobutyric Acid | 10 | 2002 | 208 | 0.940 |
Why?
|
| Reinforcement Schedule | 8 | 2014 | 59 | 0.910 |
Why?
|
| Receptors, Neuropeptide | 3 | 2012 | 22 | 0.900 |
Why?
|
| Dopamine Antagonists | 11 | 2005 | 65 | 0.860 |
Why?
|
| Globus Pallidus | 5 | 2002 | 64 | 0.850 |
Why?
|
| Heroin | 3 | 2009 | 49 | 0.840 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2012 | 75 | 0.840 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2012 | 167 | 0.820 |
Why?
|
| Microdialysis | 18 | 2013 | 147 | 0.820 |
Why?
|
| Dyskinesia, Drug-Induced | 12 | 2001 | 21 | 0.800 |
Why?
|
| Receptors, Dopamine D1 | 7 | 2009 | 87 | 0.780 |
Why?
|
| Limbic System | 3 | 2009 | 106 | 0.780 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2015 | 266 | 0.740 |
Why?
|
| Clozapine | 7 | 2002 | 46 | 0.730 |
Why?
|
| Analysis of Variance | 12 | 2013 | 1040 | 0.700 |
Why?
|
| Central Nervous System Agents | 3 | 2017 | 37 | 0.700 |
Why?
|
| Secondary Prevention | 11 | 2013 | 291 | 0.700 |
Why?
|
| Brain | 8 | 2017 | 2176 | 0.700 |
Why?
|
| Risperidone | 3 | 2009 | 48 | 0.660 |
Why?
|
| Progesterone | 3 | 2011 | 115 | 0.650 |
Why?
|
| Anti-Anxiety Agents | 2 | 2012 | 107 | 0.650 |
Why?
|
| Receptors, Dopamine | 8 | 2007 | 119 | 0.620 |
Why?
|
| Neurons | 6 | 2017 | 881 | 0.590 |
Why?
|
| Quinolones | 2 | 2009 | 60 | 0.590 |
Why?
|
| Cognition | 3 | 2016 | 513 | 0.580 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 439 | 0.560 |
Why?
|
| Estrus | 2 | 2007 | 14 | 0.550 |
Why?
|
| Piperazines | 2 | 2009 | 206 | 0.550 |
Why?
|
| Benzoxazoles | 3 | 2012 | 12 | 0.540 |
Why?
|
| Narcotics | 3 | 2009 | 65 | 0.540 |
Why?
|
| Anesthetics, Local | 4 | 2011 | 83 | 0.540 |
Why?
|
| Urea | 3 | 2012 | 51 | 0.540 |
Why?
|
| Female | 61 | 2017 | 38074 | 0.530 |
Why?
|
| Fluphenazine | 10 | 1996 | 19 | 0.530 |
Why?
|
| Models, Psychological | 3 | 2011 | 180 | 0.500 |
Why?
|
| Time Factors | 22 | 2012 | 4655 | 0.480 |
Why?
|
| Receptors, AMPA | 1 | 2014 | 99 | 0.470 |
Why?
|
| Receptors, GABA-A | 3 | 2011 | 89 | 0.470 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 413 | 0.460 |
Why?
|
| Memory | 4 | 2010 | 214 | 0.460 |
Why?
|
| Neostriatum | 4 | 2009 | 60 | 0.460 |
Why?
|
| Oncogene Proteins v-fos | 1 | 2013 | 3 | 0.450 |
Why?
|
| Electroshock | 2 | 2012 | 36 | 0.450 |
Why?
|
| Benzazepines | 8 | 2009 | 104 | 0.450 |
Why?
|
| Habenula | 1 | 2013 | 13 | 0.450 |
Why?
|
| Muscimol | 2 | 2010 | 26 | 0.430 |
Why?
|
| Baclofen | 2 | 2010 | 24 | 0.430 |
Why?
|
| Vocalization, Animal | 1 | 2012 | 4 | 0.420 |
Why?
|
| Extracellular Space | 8 | 2002 | 121 | 0.420 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 1293 | 0.420 |
Why?
|
| Guanfacine | 1 | 2012 | 6 | 0.410 |
Why?
|
| Cystine | 1 | 2012 | 20 | 0.400 |
Why?
|
| Chromatography, High Pressure Liquid | 7 | 2013 | 381 | 0.390 |
Why?
|
| Carbolines | 1 | 2011 | 19 | 0.380 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2011 | 79 | 0.380 |
Why?
|
| Public Sector | 1 | 2010 | 19 | 0.370 |
Why?
|
| Acetylcysteine | 2 | 2011 | 296 | 0.370 |
Why?
|
| Neural Pathways | 3 | 2013 | 324 | 0.370 |
Why?
|
| Septal Nuclei | 1 | 2010 | 31 | 0.360 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2010 | 71 | 0.360 |
Why?
|
| Benzodiazepines | 1 | 2011 | 130 | 0.360 |
Why?
|
| Mouth | 10 | 1998 | 64 | 0.360 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 274 | 0.350 |
Why?
|
| Cyclosporins | 1 | 2009 | 10 | 0.350 |
Why?
|
| Feeding Behavior | 1 | 2011 | 224 | 0.340 |
Why?
|
| Choice Behavior | 1 | 2010 | 85 | 0.340 |
Why?
|
| Movement | 7 | 2013 | 179 | 0.340 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 4 | 2011 | 82 | 0.330 |
Why?
|
| Cognition Disorders | 1 | 2012 | 342 | 0.330 |
Why?
|
| Tetrodotoxin | 6 | 2006 | 26 | 0.330 |
Why?
|
| Salicylamides | 7 | 1992 | 18 | 0.330 |
Why?
|
| Exploratory Behavior | 4 | 2015 | 79 | 0.320 |
Why?
|
| Attention | 1 | 2010 | 225 | 0.320 |
Why?
|
| Nicotine | 1 | 2011 | 350 | 0.310 |
Why?
|
| Muscarinic Antagonists | 2 | 2012 | 54 | 0.310 |
Why?
|
| Brain Chemistry | 4 | 2009 | 173 | 0.300 |
Why?
|
| Caloric Restriction | 1 | 2007 | 22 | 0.300 |
Why?
|
| Heroin Dependence | 1 | 2007 | 23 | 0.300 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 432 | 0.280 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 213 | 0.280 |
Why?
|
| Association | 1 | 2005 | 5 | 0.270 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 154 | 0.260 |
Why?
|
| Photic Stimulation | 3 | 2014 | 229 | 0.260 |
Why?
|
| Nerve Net | 1 | 2007 | 181 | 0.260 |
Why?
|
| Alcoholism | 2 | 2011 | 1109 | 0.260 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 805 | 0.260 |
Why?
|
| Dietary Sucrose | 2 | 2015 | 18 | 0.250 |
Why?
|
| Rats, Inbred Strains | 16 | 1991 | 532 | 0.240 |
Why?
|
| Receptors, Dopamine D2 | 5 | 2005 | 109 | 0.240 |
Why?
|
| Models, Animal | 3 | 2010 | 252 | 0.240 |
Why?
|
| Receptors, Muscarinic | 2 | 2003 | 44 | 0.240 |
Why?
|
| Dextroamphetamine | 2 | 2003 | 30 | 0.230 |
Why?
|
| Orexin Receptors | 3 | 2012 | 11 | 0.230 |
Why?
|
| Neurotransmitter Agents | 2 | 2008 | 102 | 0.230 |
Why?
|
| Naphthyridines | 3 | 2012 | 20 | 0.230 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 9 | 2009 | 40 | 0.230 |
Why?
|
| Food | 3 | 2010 | 52 | 0.220 |
Why?
|
| Neurotensin | 3 | 2005 | 37 | 0.220 |
Why?
|
| Frontal Lobe | 1 | 2004 | 156 | 0.220 |
Why?
|
| Maze Learning | 2 | 2013 | 138 | 0.210 |
Why?
|
| Presynaptic Terminals | 1 | 2002 | 34 | 0.210 |
Why?
|
| Raclopride | 8 | 2001 | 15 | 0.200 |
Why?
|
| Receptors, Neurotensin | 2 | 2005 | 17 | 0.200 |
Why?
|
| Estradiol | 2 | 2007 | 176 | 0.200 |
Why?
|
| Catalepsy | 4 | 2009 | 8 | 0.190 |
Why?
|
| Dialysis | 8 | 1992 | 30 | 0.190 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2001 | 30 | 0.190 |
Why?
|
| Sex Factors | 3 | 2016 | 1266 | 0.190 |
Why?
|
| Drug Administration Schedule | 4 | 2011 | 567 | 0.190 |
Why?
|
| Basal Ganglia | 2 | 2007 | 45 | 0.190 |
Why?
|
| Norepinephrine | 2 | 1999 | 276 | 0.180 |
Why?
|
| Acetylcholine | 1 | 2001 | 64 | 0.180 |
Why?
|
| Serotonin Antagonists | 1 | 2000 | 31 | 0.180 |
Why?
|
| Seizures | 2 | 2013 | 279 | 0.180 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2012 | 32 | 0.180 |
Why?
|
| Humans | 14 | 2021 | 68618 | 0.180 |
Why?
|
| Drug Interactions | 4 | 2012 | 289 | 0.170 |
Why?
|
| Schizophrenic Psychology | 1 | 1999 | 53 | 0.170 |
Why?
|
| Corticosterone | 2 | 2011 | 51 | 0.160 |
Why?
|
| Homovanillic Acid | 7 | 1993 | 52 | 0.160 |
Why?
|
| Action Potentials | 2 | 2010 | 223 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2017 | 114 | 0.160 |
Why?
|
| Acoustic Stimulation | 3 | 2005 | 206 | 0.160 |
Why?
|
| N-Methylaspartate | 1 | 1998 | 59 | 0.150 |
Why?
|
| Dopamine Agents | 5 | 2009 | 56 | 0.150 |
Why?
|
| Aripiprazole | 2 | 2009 | 43 | 0.150 |
Why?
|
| Schizophrenia | 1 | 1999 | 206 | 0.150 |
Why?
|
| Pilocarpine | 3 | 2012 | 9 | 0.150 |
Why?
|
| Drug Tolerance | 5 | 2000 | 80 | 0.150 |
Why?
|
| Piperidines | 2 | 2015 | 123 | 0.150 |
Why?
|
| Dominance, Cerebral | 1 | 1997 | 65 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 334 | 0.150 |
Why?
|
| Estrogens | 1 | 1998 | 173 | 0.150 |
Why?
|
| Peptide Fragments | 2 | 2005 | 483 | 0.150 |
Why?
|
| Hydroxyindoleacetic Acid | 5 | 1998 | 36 | 0.140 |
Why?
|
| Cerebral Cortex | 2 | 2012 | 415 | 0.140 |
Why?
|
| Catheterization | 3 | 2005 | 209 | 0.140 |
Why?
|
| Vagina | 1 | 1997 | 88 | 0.140 |
Why?
|
| Arousal | 1 | 1997 | 168 | 0.140 |
Why?
|
| Metoclopramide | 1 | 1996 | 21 | 0.140 |
Why?
|
| Quinolines | 1 | 1996 | 48 | 0.140 |
Why?
|
| Infusions, Intraventricular | 2 | 2016 | 8 | 0.130 |
Why?
|
| Cell Division | 1 | 1997 | 541 | 0.130 |
Why?
|
| Sucrose | 1 | 2016 | 58 | 0.130 |
Why?
|
| Fourier Analysis | 6 | 1994 | 31 | 0.130 |
Why?
|
| Amino Acids | 1 | 1996 | 131 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 175 | 0.130 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.130 |
Why?
|
| RNA, Messenger | 4 | 2012 | 1664 | 0.130 |
Why?
|
| Early Growth Response Protein 1 | 3 | 2010 | 42 | 0.130 |
Why?
|
| Injections, Subcutaneous | 3 | 2002 | 87 | 0.130 |
Why?
|
| Pyrazoles | 1 | 1996 | 190 | 0.130 |
Why?
|
| Locomotion | 1 | 2016 | 135 | 0.120 |
Why?
|
| Cytoskeletal Proteins | 3 | 2010 | 108 | 0.120 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2015 | 32 | 0.120 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2011 | 51 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 83 | 0.120 |
Why?
|
| Injections, Intraventricular | 2 | 2006 | 50 | 0.120 |
Why?
|
| Dopamine Agonists | 1 | 1994 | 68 | 0.120 |
Why?
|
| Injections | 2 | 2005 | 119 | 0.120 |
Why?
|
| Eating | 1 | 2015 | 119 | 0.120 |
Why?
|
| Depression | 1 | 2021 | 943 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2014 | 1200 | 0.120 |
Why?
|
| Punishment | 1 | 2014 | 25 | 0.120 |
Why?
|
| Sodium Channels | 2 | 2006 | 24 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2009 | 260 | 0.110 |
Why?
|
| GABA Agonists | 1 | 2013 | 23 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 3 | 2010 | 290 | 0.110 |
Why?
|
| Potassium | 3 | 2001 | 168 | 0.110 |
Why?
|
| Sodium Channel Blockers | 2 | 2005 | 23 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2013 | 1330 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2013 | 249 | 0.110 |
Why?
|
| Homeostasis | 2 | 2011 | 291 | 0.100 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 257 | 0.100 |
Why?
|
| Synaptotagmins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Desipramine | 1 | 1992 | 47 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 1993 | 231 | 0.100 |
Why?
|
| Muscarinic Agonists | 1 | 2012 | 17 | 0.100 |
Why?
|
| Functional Laterality | 1 | 2013 | 240 | 0.100 |
Why?
|
| Adult | 5 | 2013 | 21403 | 0.100 |
Why?
|
| Kainic Acid | 1 | 2012 | 44 | 0.100 |
Why?
|
| Sympathomimetics | 1 | 2012 | 16 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2021 | 7029 | 0.100 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2011 | 21 | 0.100 |
Why?
|
| Angiotensins | 1 | 2011 | 16 | 0.100 |
Why?
|
| Drinking Behavior | 1 | 2011 | 20 | 0.100 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2011 | 92 | 0.100 |
Why?
|
| Parasympathetic Nervous System | 1 | 1991 | 14 | 0.100 |
Why?
|
| Beer | 1 | 2011 | 6 | 0.100 |
Why?
|
| Young Adult | 3 | 2011 | 5717 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2011 | 96 | 0.090 |
Why?
|
| Allosteric Regulation | 1 | 2010 | 58 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2010 | 2689 | 0.090 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2010 | 51 | 0.090 |
Why?
|
| Long-Term Potentiation | 1 | 2010 | 53 | 0.090 |
Why?
|
| Pyramidal Cells | 1 | 2010 | 79 | 0.090 |
Why?
|
| Synapses | 1 | 1992 | 222 | 0.090 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1990 | 31 | 0.090 |
Why?
|
| Biophysics | 1 | 2009 | 41 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 14 | 0.090 |
Why?
|
| Biogenic Monoamines | 1 | 2009 | 18 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 329 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2008 | 124 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2010 | 236 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 649 | 0.080 |
Why?
|
| Neuropeptides | 1 | 2009 | 106 | 0.080 |
Why?
|
| Movement Disorders | 1 | 1989 | 58 | 0.080 |
Why?
|
| Body Weight | 3 | 2007 | 554 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 216 | 0.080 |
Why?
|
| Ovariectomy | 2 | 1998 | 49 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.080 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2007 | 15 | 0.080 |
Why?
|
| Stereotaxic Techniques | 1 | 2007 | 35 | 0.080 |
Why?
|
| Multiple Chemical Sensitivity | 2 | 1998 | 5 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 517 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 955 | 0.070 |
Why?
|
| RGS Proteins | 1 | 2007 | 22 | 0.070 |
Why?
|
| Taurine | 1 | 2007 | 51 | 0.070 |
Why?
|
| Formaldehyde | 2 | 1998 | 48 | 0.070 |
Why?
|
| Up-Regulation | 1 | 1990 | 682 | 0.070 |
Why?
|
| Infusion Pumps, Implantable | 2 | 2000 | 26 | 0.070 |
Why?
|
| Alcohol Deterrents | 1 | 2007 | 86 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2007 | 102 | 0.070 |
Why?
|
| Mental Recall | 1 | 2007 | 72 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 1046 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 164 | 0.070 |
Why?
|
| Administration, Intravenous | 2 | 2016 | 89 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2007 | 219 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2007 | 396 | 0.070 |
Why?
|
| Glycine | 2 | 1996 | 89 | 0.070 |
Why?
|
| Mastication | 2 | 2000 | 7 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 498 | 0.070 |
Why?
|
| Ergolines | 5 | 1992 | 19 | 0.060 |
Why?
|
| Physical Stimulation | 1 | 2005 | 67 | 0.060 |
Why?
|
| Taste | 1 | 2005 | 49 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2007 | 447 | 0.060 |
Why?
|
| Middle Aged | 3 | 2011 | 21147 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2005 | 99 | 0.060 |
Why?
|
| Autoradiography | 3 | 2008 | 94 | 0.060 |
Why?
|
| Ethanol | 1 | 2011 | 893 | 0.060 |
Why?
|
| Models, Neurological | 2 | 2003 | 136 | 0.060 |
Why?
|
| Diet | 1 | 2007 | 514 | 0.060 |
Why?
|
| Nomifensine | 2 | 1994 | 2 | 0.060 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2016 | 532 | 0.060 |
Why?
|
| Spiperone | 2 | 1996 | 29 | 0.050 |
Why?
|
| Amphetamine | 2 | 1993 | 77 | 0.050 |
Why?
|
| Forelimb | 1 | 2002 | 15 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2002 | 22 | 0.050 |
Why?
|
| Hindlimb | 1 | 2002 | 38 | 0.050 |
Why?
|
| Neural Inhibition | 1 | 2002 | 80 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 170 | 0.050 |
Why?
|
| Neurobiology | 1 | 2021 | 9 | 0.050 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 2001 | 9 | 0.050 |
Why?
|
| Pregnancy | 1 | 2007 | 2334 | 0.050 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2001 | 12 | 0.050 |
Why?
|
| Quinpirole | 5 | 1992 | 26 | 0.050 |
Why?
|
| Cell Count | 1 | 2001 | 248 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2001 | 128 | 0.050 |
Why?
|
| Child | 1 | 2010 | 6405 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1174 | 0.040 |
Why?
|
| Microinjections | 2 | 2016 | 130 | 0.040 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 4 | 1991 | 15 | 0.040 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1998 | 5 | 0.040 |
Why?
|
| United States | 1 | 2010 | 7367 | 0.040 |
Why?
|
| Aged | 2 | 2010 | 14862 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 1998 | 51 | 0.040 |
Why?
|
| Electrodes, Implanted | 1 | 1998 | 98 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2008 | 689 | 0.040 |
Why?
|
| Adolescent | 1 | 2010 | 8912 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2008 | 201 | 0.040 |
Why?
|
| Calcium | 1 | 2001 | 929 | 0.040 |
Why?
|
| Regression Analysis | 1 | 1999 | 737 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Gene Expression | 2 | 2010 | 770 | 0.030 |
Why?
|
| Isoflurane | 1 | 2016 | 16 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 2016 | 21 | 0.030 |
Why?
|
| Motor Cortex | 1 | 1998 | 158 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1996 | 189 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1995 | 57 | 0.030 |
Why?
|
| Drug Implants | 1 | 1995 | 19 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 1995 | 22 | 0.030 |
Why?
|
| Repetition Priming | 1 | 2015 | 2 | 0.030 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2015 | 20 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1999 | 1738 | 0.030 |
Why?
|
| Cycloserine | 1 | 2015 | 30 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 62 | 0.030 |
Why?
|
| Actins | 1 | 1996 | 249 | 0.030 |
Why?
|
| Phenols | 1 | 2015 | 73 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 296 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 386 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1994 | 218 | 0.030 |
Why?
|
| Drinking | 2 | 1990 | 35 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1994 | 411 | 0.030 |
Why?
|
| Sulpiride | 2 | 1989 | 20 | 0.030 |
Why?
|
| Oxotremorine | 1 | 1991 | 6 | 0.020 |
Why?
|
| Parasympathomimetics | 1 | 1991 | 13 | 0.020 |
Why?
|
| Physostigmine | 1 | 1991 | 14 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 371 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1993 | 954 | 0.020 |
Why?
|
| Dibenzazepines | 1 | 1990 | 1 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 204 | 0.020 |
Why?
|
| Grooming | 1 | 1990 | 5 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 260 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2009 | 67 | 0.020 |
Why?
|
| Biological Transport | 1 | 2009 | 210 | 0.020 |
Why?
|
| Tic Disorders | 1 | 1989 | 3 | 0.020 |
Why?
|
| Orexins | 1 | 2009 | 52 | 0.020 |
Why?
|
| Genes, fos | 1 | 2008 | 22 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 25 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2223 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 280 | 0.020 |
Why?
|
| Morphine | 1 | 1987 | 76 | 0.020 |
Why?
|
| Pain Measurement | 2 | 1998 | 328 | 0.020 |
Why?
|
| Hypothermia | 1 | 2005 | 37 | 0.020 |
Why?
|
| Pain | 1 | 1987 | 472 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 2800 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 2791 | 0.010 |
Why?
|
| Avoidance Learning | 1 | 1996 | 58 | 0.010 |
Why?
|
| Consciousness | 1 | 1992 | 17 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 8474 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1989 | 124 | 0.010 |
Why?
|
| Head | 1 | 1989 | 59 | 0.010 |
Why?
|
| Face | 1 | 1989 | 46 | 0.010 |
Why?
|
| Data Collection | 1 | 1989 | 420 | 0.000 |
Why?
|
| Methods | 1 | 1987 | 156 | 0.000 |
Why?
|